# EDGAR Filing Document

**Accession Number:** 0001639078
**File Stem:** 0001171843-23-000890
**Filing Date:** 2023-2
**Character Count:** 8232
**Document Hash:** ee8308c3efa8f65b577b299b3b56e785
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000890.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0001171843-23-000890

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XBiotech Inc.
- **CENTRAL INDEX KEY:** 0001626878
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88810
- **FILM NUMBER:** 23609791

**BUSINESS ADDRESS:**
- **STREET 1:** 5217 WINNEBAGO LANE
- **STREET 2:** BUILDING 4, SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78744
- **BUSINESS PHONE:** 512-386-2900

**MAIL ADDRESS:**
- **STREET 1:** 5217 WINNEBAGO LANE
- **STREET 2:** BUILDING 4, SUITE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78744
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SIMARD JOHN
- **CENTRAL INDEX KEY:** 0001639078

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**MAIL ADDRESS:**
- **STREET 1:** 8201 E RIVERSIDE DRIVE
- **STREET 2:** BLDG 4, STE 100
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78744

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

**** 

**** 

---

| |
|:---|
| **XBIOTECH INC.** |
| (Name of Issuer)<br>|
| **Common Shares, no par value** |
| (Title of Class of Securities)<br>|
| **98400H102** |
| (CUSIP Number)<br>|
| **December 31, 2022** |
| (Date of Event which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[x] Rule 13d-1(d)

<sup>1</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

SCHEDULE 13G

---

| | | | |
|:---|:---|:---|:---|
| **CUSIP No.** | **98400H102** | **98400H102** | **98400H102** |
| **1** | **Names of Reporting Persons** | **Names of Reporting Persons** | **Names of Reporting Persons** |
|  | <br> John Simard  | <br> John Simard  | <br> John Simard  |
| **2** | **Check the appropriate box if a member of a Group (see instructions)** | **Check the appropriate box if a member of a Group (see instructions)** | **Check the appropriate box if a member of a Group (see instructions)** |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [ ] | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [ ] | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) [ ] |
| **3** | **Sec Use Only** | **Sec Use Only** | **Sec Use Only** |
| **4** | **Citizenship or Place of Organization** | **Citizenship or Place of Organization** | **Citizenship or Place of Organization** |
|  | Canada | Canada | Canada |
|  |  | **5** | &nbsp;&nbsp;&nbsp;**Sole Voting Power** |
|  |  |  | &nbsp;&nbsp;&nbsp;5193547 <sup>(1)</sup> |
| **Number of Shares** | **Number of Shares** | **6** | &nbsp;&nbsp;&nbsp;**Shared Voting Power** |
| **Beneficially Owned** | **Beneficially Owned** |  |  |
| **by Each Reporting** | **by Each Reporting** |  | &nbsp;&nbsp;&nbsp;N/A |
| **Person With:** | **Person With:** | **7** | &nbsp;&nbsp;&nbsp;**Sole Dispositive Power** |
|  |  |  | &nbsp;&nbsp;&nbsp;5193547 <sup>(1)</sup> |
|  |  | **8** | &nbsp;&nbsp;&nbsp;**Shared Dispositive Power** |
|  |  |  | &nbsp;&nbsp;&nbsp;N/A |
| **9** | **Aggregate Amount Beneficially Owned by Each Reporting Person** | **Aggregate Amount Beneficially Owned by Each Reporting Person** | **Aggregate Amount Beneficially Owned by Each Reporting Person** |
|  | 5193547 <sup>(1)</sup> | 5193547 <sup>(1)</sup> | 5193547 <sup>(1)</sup> |
| **10** | **Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)** | **Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)** | **Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)** |
|  | [ ] | [ ] | [ ] |
| **11** | **Percent of class represented by amount in row (9)** | **Percent of class represented by amount in row (9)** | **Percent of class represented by amount in row (9)** |
|  | 16.33%<sup>(2)</sup> | 16.33%<sup>(2)</sup> | 16.33%<sup>(2)</sup> |
| **12** | **Type of Reporting Person (See Instructions)** | **Type of Reporting Person (See Instructions)** | **Type of Reporting Person (See Instructions)** |
|  | IN | IN | IN |

---

(1) These figures include shares of common stock underlying stock options held by the Reporting Person, including options which are immediately exercisable within 60 days of December 31, 2022.

(2) The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

2 of 5

**Item 1.**

**(a)** **Name of Issuer:** 

XBiotech Inc.

**(b)** **Address of Issuer's Principal Executive Offices:** 

5217 Winnebago Ln, Austin, TX 78744

**Item 2.**

**(a)** **Name of Person Filing:** 

John Simard

**(b)** **Address of Principal Business Office or, if None, Residence:** 

5217 Winnebago Ln, Austin, TX 78744

**(c)** **Citizenship:** 

Canada

**(d)** **Title and Class of Securities:** 

Common Shares, no par value

**(e)** **CUSIP No.:** 

98400H102

**Item 3.** **If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

Not Applicable

**Item 4.** **Ownership**

As of December 31, 2022

**(a)** **Amount Beneficially Owned:** 

5,193,547<sup>(1)</sup> shares

**(b)** **Percent of Class:** 

16.33%<sup>(2)</sup>

**(c) Number of shares as to which such person has:**

**(i)** **Sole power to vote or to direct the vote:** 

5,193,547 <sup>(1)</sup> shares

3 of 5

**(ii)** **Shared power to vote or to direct the vote:** 

Not Applicable

**(iii)** **Sole power to dispose or to direct the disposition of:** 

5,193,547 <sup>(1)</sup> shares

**(iv)** **Shared power to dispose or to direct the disposition of:** 

Not Applicable

(1) These figures include shares of common stock underlying stock options held by the Reporting Person, including options which are immediately exercisable within 60 days of December 31, 2022.

(2) The percentage is calculated based upon 30,439,275 shares outstanding as of December 31, 2022.

**Item 5.** **Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

**Item 6.** **Ownership of more than Five Percent on Behalf of Another Person.**

Not Applicable

**Item 7.** **Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.**

Not Applicable

**Item 8.** **Identification and classification of members of the group.**

Not Applicable

**Item 9.** **Notice of Dissolution of Group.**

Not Applicable

**Item 10.** **Certifications.**

Not Applicable

4 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2023

*<u>/s/ John Simard</u>*

 

John Simard/President & CEO, XBiotech Inc.

5 of 5